Phathom Pharmaceuticals Inc
PHATHealthcare|Biotechnology|USA
$12.61
+0.45 (+3.70%)
Upcoming Data Readouts (4)
Oct 2026
Est. completion
P2Eosinophilic Esophagitis
A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks
NCT06851559n=95
Nov 2027
Est. completion
P4H. Pylori Infection
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community-AIM 2
NCT07224048n=75
Nov 2027
Est. completion
P4H Pylori Infection
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
NCT07224035n=500
Sep 2034
Est. completion
Erosive Esophagitis
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
NCT06660342n=728